Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

NCT03460977 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03460977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03460977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Recruiting
Start date
April 17, 2018
Completion date
July 7, 2029
Enrollment
453 (estimated)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma (fl), metastatic castration resistant prostate cancer (mcrpc), small cell lung cancer (sclc)